Dysregulated Signaling Pathways in the Development of CNTRL-FGFR1-induced Myeloid and Lymphoid Malignancies Associated with FGFR1 in Human and Mouse Models

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2013 Jun 20

PMID 23777766

Citations 23

Authors

Mingqiang Ren

Haiyan Qin

Eiko Kitamura

John K Cowell

Affiliations

Soon will be listed here.

Abstract

Myeloid and lymphoid neoplasm associated with FGFR1 is an aggressive disease, and resistant to all the current chemotherapies. To define the molecular etiology of this disease, we have developed murine models of this disease, in syngeneic hosts as well as in nonobese diabetic/severe combined immunodeficiency/interleukin 2Rγ(null) mice engrafted with transformed human CD34+ hematopoietic stem/progenitor cells. Both murine models mimic the human disease with splenohepatomegaly, hypercellular bone marrow, and myeloproliferative neoplasms that progresses to acute myeloid leukemia. Molecular genetic analyses of these model mice, as well as primary human disease, demonstrated that CNTRL-FGFR1, through abnormal activation of several signaling pathways related to development and differentiation of both myeloid and T-lymphoid cells, contribute to overt leukemogenesis. Clonal evolution analysis indicates that myeloid related neoplasms arise from common myeloid precursor cells that retain potential for T-lymphoid differentiation. These data indicate that simultaneously targeting these pathways is essential to successfully treating this almost invariably lethal disease.

Citing Articles

Single-cell analysis defines highly specific leukemia-induced neutrophils and links MMP8 expression to recruitment of tumor associated neutrophils during FGFR1 driven leukemogenesis.

Hu T, Cheng B, Matsunaga A, Zhang T, Lu X, Fang H Exp Hematol Oncol. 2024; 13(1):49.

PMID: 38730491 PMC: 11084112. DOI: 10.1186/s40164-024-00514-6.

Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy.

Lang Y, Lyu Y, Tan Y, Hu Z Front Immunol. 2023; 14:1195194.

PMID: 37646021 PMC: 10461088. DOI: 10.3389/fimmu.2023.1195194.

A truncated derivative of FGFR1 kinase cooperates with FLT3 and KIT to transform hematopoietic stem cells in syndromic and de novo AML.

Cai B, Liu Y, Chong Y, Mori S, Matsunaga A, Zhang H Mol Cancer. 2022; 21(1):156.

PMID: 35906694 PMC: 9336057. DOI: 10.1186/s12943-022-01628-3.

RHOA-regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia.

Zhang H, Cai B, Liu Y, Chong Y, Matsunaga A, Mori S Haematologica. 2022; 108(1):122-134.

PMID: 35833297 PMC: 9827165. DOI: 10.3324/haematol.2022.280757.

CCDC88C-FLT3 gene fusion in CD34-positive haematopoietic stem and multilineage cells in myeloid/lymphoid neoplasm with eosinophilia.

Kurihara Y, Mizuno H, Honda A, Shimura A, Fujioka Y, Maki H J Cell Mol Med. 2022; 26(3):950-952.

PMID: 35019216 PMC: 8817136. DOI: 10.1111/jcmm.17143.

References

Delmore J, Issa G, Lemieux M, Rahl P, Shi J, Jacobs H . BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011; 146(6):904-17. PMC: 3187920. DOI: 10.1016/j.cell.2011.08.017. View

Mombaerts P, Mizoguchi E, Grusby M, Glimcher L, Bhan A, Tonegawa S . Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell. 1993; 75(2):274-82. DOI: 10.1016/0092-8674(93)80069-q. View

Santos P, Borghesi L . Molecular resolution of the B cell landscape. Curr Opin Immunol. 2011; 23(2):163-70. PMC: 3073704. DOI: 10.1016/j.coi.2010.11.014. View

Ren M, Cowell J . Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease. Blood. 2011; 117(25):6837-47. PMC: 3128478. DOI: 10.1182/blood-2010-07-295725. View

Yamamoto K, Kawano H, Nishikawa S, Yakushijin K, Okamura A, Matsui T . A biphenotypic transformation of 8p11 myeloproliferative syndrome with CEP1/FGFR1 fusion gene. Eur J Haematol. 2006; 77(4):349-54. DOI: 10.1111/j.1600-0609.2006.00723.x. View

Krawczuk-Rybak M, Zak J, Jaworowska B . A lineage switch from AML to ALL with persistent translocation t(4;11) in congenital leukemia. Med Pediatr Oncol. 2003; 41(1):95-6. DOI: 10.1002/mpo.10276. View

Chen J, DeAngelo D, Kutok J, Williams I, Lee B, Wadleigh M . PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A. 2004; 101(40):14479-84. PMC: 521956. DOI: 10.1073/pnas.0404438101. View

Wei J, Wunderlich M, Fox C, Alvarez S, Cigudosa J, Wilhelm J . Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell. 2008; 13(6):483-95. PMC: 2486365. DOI: 10.1016/j.ccr.2008.04.020. View

Post G, Holloman D, Christiansen L, Smith J, Stuart R, Lazarchick J . Translocation t(3;8;9)(p25;p21;q34) in a patient with features of 8p11 myeloproliferative syndrome: a unique case and review of the literature. Leuk Res. 2010; 34(11):1543-4. DOI: 10.1016/j.leukres.2010.05.017. View

10.

Zhou L, Fu W, Yuan Z, Hou J . Complete molecular remission after interferon alpha treatment in a case of 8p11 myeloproliferative syndrome. Leuk Res. 2010; 34(11):e306-7. DOI: 10.1016/j.leukres.2010.06.027. View

11.

Ren M, Li X, Cowell J . Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase. Blood. 2009; 114(8):1576-84. PMC: 2731638. DOI: 10.1182/blood-2009-03-212704. View

12.

Hoffman B, Amanullah A, Shafarenko M, Liebermann D . The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene. 2002; 21(21):3414-21. DOI: 10.1038/sj.onc.1205400. View

13.

Luo H, Li Q, ONeal J, Kreisel F, Le Beau M, Tomasson M . c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood. 2005; 106(7):2452-61. DOI: 10.1182/blood-2005-02-0734. View

14.

Risueno R, Campbell C, Dingwall S, Levadoux-Martin M, Leber B, Xenocostas A . Identification of T-lymphocytic leukemia-initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease. Blood. 2011; 117(26):7112-20. DOI: 10.1182/blood-2011-01-329078. View

15.

Lounici A, Cony-Makhoul P, Dubus P, Lacombe F, Merlio J, Reiffers J . Lineage switch from acute myeloid leukemia to acute lymphoblastic leukemia: report of an adult case and review of the literature. Am J Hematol. 2000; 65(4):319-21. DOI: 10.1002/1096-8652(200012)65:4<319::aid-ajh13>3.0.co;2-1. View

16.

Stirewalt D, Radich J . The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003; 3(9):650-65. DOI: 10.1038/nrc1169. View

17.

Agerstam H, Jaras M, Andersson A, Johnels P, Hansen N, Lassen C . Modeling the human 8p11-myeloproliferative syndrome in immunodeficient mice. Blood. 2010; 116(12):2103-11. DOI: 10.1182/blood-2009-05-217182. View

18.

OHare T, Shakespeare W, Zhu X, Eide C, Rivera V, Wang F . AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009; 16(5):401-12. PMC: 2804470. DOI: 10.1016/j.ccr.2009.09.028. View

19.

Shultz L, Lyons B, Burzenski L, Gott B, Chen X, Chaleff S . Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005; 174(10):6477-89. DOI: 10.4049/jimmunol.174.10.6477. View

20.

Katsura Y . Redefinition of lymphoid progenitors. Nat Rev Immunol. 2002; 2(2):127-32. DOI: 10.1038/nri721. View